Shanghai Titan Scientific Balance Sheet Health
Financial Health criteria checks 3/6
Shanghai Titan Scientific has a total shareholder equity of CN¥2.9B and total debt of CN¥1.5B, which brings its debt-to-equity ratio to 51.6%. Its total assets and total liabilities are CN¥4.8B and CN¥2.0B respectively. Shanghai Titan Scientific's EBIT is CN¥19.5M making its interest coverage ratio 0.7. It has cash and short-term investments of CN¥978.4M.
Key information
51.6%
Debt to equity ratio
CN¥1.47b
Debt
Interest coverage ratio | 0.7x |
Cash | CN¥978.44m |
Equity | CN¥2.86b |
Total liabilities | CN¥1.98b |
Total assets | CN¥4.85b |
Recent financial health updates
Recent updates
Shanghai Titan Scientific (SHSE:688133) Has A Somewhat Strained Balance Sheet
Dec 17Shanghai Titan Scientific Co., Ltd.'s (SHSE:688133) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Oct 01Shanghai Titan Scientific's (SHSE:688133) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Sep 05Returns On Capital Signal Tricky Times Ahead For Shanghai Titan Scientific (SHSE:688133)
Aug 30Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Not Flying Under The Radar
Aug 07At CN¥16.04, Is Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Worth Looking At Closely?
Jun 28Shanghai Titan Scientific Co., Ltd.'s (SHSE:688133) Stock Retreats 27% But Earnings Haven't Escaped The Attention Of Investors
Apr 16Should You Think About Buying Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Now?
Mar 26Financial Position Analysis
Short Term Liabilities: 688133's short term assets (CN¥3.2B) exceed its short term liabilities (CN¥1.5B).
Long Term Liabilities: 688133's short term assets (CN¥3.2B) exceed its long term liabilities (CN¥460.4M).
Debt to Equity History and Analysis
Debt Level: 688133's net debt to equity ratio (17.4%) is considered satisfactory.
Reducing Debt: 688133's debt to equity ratio has increased from 30.9% to 51.6% over the past 5 years.
Debt Coverage: 688133's debt is not well covered by operating cash flow (6.3%).
Interest Coverage: 688133's interest payments on its debt are not well covered by EBIT (0.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 23:31 |
End of Day Share Price | 2025/01/02 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Titan Scientific Co., Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tangyi Li | China International Capital Corporation Limited |
Shitong Han | Citic Securities Co., Ltd. |
Weijia Wang | Huatai Research |